Bisphosphonate use and risk of post-operative fracture among patients undergoing a total knee replacement for knee osteoarthritis: a propensity score analysis
- PMID: 20694456
- DOI: 10.1007/s00198-010-1368-1
Bisphosphonate use and risk of post-operative fracture among patients undergoing a total knee replacement for knee osteoarthritis: a propensity score analysis
Abstract
Summary: We have shown that patients with osteoarthritis are at increased risk of fracture after total knee replacement (TKR). We conducted a population-based cohort study to assess the effect of bisphosphonate use on their post-surgery fracture risk. Cox regression adjusted by propensity score suggested a 50-55% reduction in risk of fracture post-surgery.
Introduction: Patients with osteoarthritis have a higher bone mass but similar or higher risk of fracture. We recently demonstrated that patients have an elevated fracture risk after TKR, but it is unknown if bisphosphonate therapy in this patient group would reduce fracture risk. We aimed to assess the effect of bisphosphonate prescription to patients undergoing a TKR, on their risk of fracture after surgery.
Methods: From the General Practice Research Database, all patients ≥ 40 years old, who received a TKR from 1986 to 2006 for knee osteoarthritis were eligible. We identified bisphosphonate use (BPU) as the main exposure. Propensity scores (equivalent to the estimated conditional probability of being treated given the individual's covariates) were calculated using logistic regression and used to reduce observed confounding. We fitted Cox models to study the effect of BPU on post-surgery fracture occurrence. Analyses were stratified by history of previous fracture: no fracture, osteoporotic fracture (hip, wrist, humerus, spine), and other fractures.
Results: The hazard ratio (HR) associated with BPU in non-previously fractured patients was 0.50 (95% confidence interval, 0.37-0.68; propensity-adjusted model), and 0.48 (0.35-0.65; matched analysis). In subjects with osteoporotic and with other previous fracture, BPU was associated with a propensity-adjusted HR of 0.46 (0.30 to 0.71) and 0.47 (0.26-0.85), respectively, and with a propensity-matched HR of 0.45 (0.29 to 0.70) and 0.45 (0.25-0.82).
Conclusion: Our results suggest that BPU in primary prevention could reduce post-operative risk of fracture by 50% and by 55% in secondary prevention.
Similar articles
-
Fracture risk before and after total hip replacement in patients with osteoarthritis: potential benefits of bisphosphonate use.Arthritis Rheum. 2011 Apr;63(4):992-1001. doi: 10.1002/art.30214. Arthritis Rheum. 2011. PMID: 21452321
-
Bisphosphonate Use and the Risk of Undergoing Total Knee Arthroplasty in Osteoporotic Patients with Osteoarthritis: A Nationwide Cohort Study in Taiwan.J Bone Joint Surg Am. 2017 Jun 7;99(11):938-946. doi: 10.2106/JBJS.16.00385. J Bone Joint Surg Am. 2017. PMID: 28590379
-
Bisphosphonate use after clinical fracture and risk of new fracture.Osteoporos Int. 2018 Apr;29(4):937-945. doi: 10.1007/s00198-017-4367-7. Epub 2018 Feb 3. Osteoporos Int. 2018. PMID: 29397408 Free PMC article.
-
Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.Health Technol Assess. 2020 Jun;24(29):1-314. doi: 10.3310/hta24290. Health Technol Assess. 2020. PMID: 32588816 Free PMC article.
-
A systematic review and meta-analysis of the effect of bisphosphonate drug holidays on bone mineral density and osteoporotic fracture risk.Osteoporos Int. 2019 Apr;30(4):705-720. doi: 10.1007/s00198-018-4791-3. Epub 2019 Jan 8. Osteoporos Int. 2019. PMID: 30623214 Free PMC article.
Cited by
-
Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study.Health Technol Assess. 2021 Mar;25(17):1-106. doi: 10.3310/hta25170. Health Technol Assess. 2021. PMID: 33739919 Free PMC article.
-
Osteoporosis and orthopedic surgery: effect of bone health on total joint arthroplasty outcome.Curr Rheumatol Rep. 2013 Nov;15(11):371. doi: 10.1007/s11926-013-0371-x. Curr Rheumatol Rep. 2013. PMID: 24085661 Review.
-
QCT bone mineral density responses to 1 year of oral bisphosphonate after total knee replacement for knee osteoarthritis.Osteoporos Int. 2013 Jan;24(1):287-92. doi: 10.1007/s00198-012-1925-x. Epub 2012 Feb 23. Osteoporos Int. 2013. PMID: 22358316 Clinical Trial.
-
Association between bisphosphonate use and implant survival after primary total arthroplasty of the knee or hip: population based retrospective cohort study.BMJ. 2011 Dec 6;343:d7222. doi: 10.1136/bmj.d7222. BMJ. 2011. PMID: 22147909 Free PMC article.
-
Comparative anti-fracture effectiveness of different oral anti-osteoporosis therapies based on "real-world" data: a meta-analysis of propensity-matched cohort findings from the UK Clinical Practice Research Database and the Catalan SIDIAP Database.Clin Epidemiol. 2018 Oct 9;10:1417-1431. doi: 10.2147/CLEP.S164112. eCollection 2018. Clin Epidemiol. 2018. PMID: 30349390 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical